Semaglutide as a Preferred Treatment for Diabetes in a Patient with CKD

Semaglutide offers proven cardiovascular and renal benefits, which are crucial for diabetes patients with chronic kidney disease (CKD) due to their elevated risk of cardiovascular complications. This benefit was a key factor in its selection.

A glucagon-like peptide-1 (GLP-1) receptor agonist, specifically semaglutide, was chosen for a patient named Ty after evaluating her clinical presentation, lab findings, and comorbid conditions. Her A1C of 8.5% indicated a need for improved glycemic control, and GLP-1 receptor agonists are highly effective, reducing A1C by 1% to 2%.

Ty's eGFR of 26 mL/min/1.73 m² influenced the medication choice. Metformin is not recommended below 30 mL/min/1.73 m², and many other oral agents need dose adjustments or are less effective in advanced kidney disease. GLP-1 receptor agonists are suitable for advanced CKD and safe for eGFRs above 15 mL/min/1.73 m².

Ty's history of medication nonadherence was a significant consideration. The once-weekly injection of semaglutide simplifies the treatment regimen, potentially improving adherence compared to daily oral medications or more complex insulin regimens. Possible cognitive impairment further supported selecting a therapy that minimized the treatment burden.